1. Van de Beek D. Acute and chronic meningitis. In: Cohen J, Powderly WG, Opal SM (Eds). Infectious Diseases. Third ed, Philadelphia; Mosby (Elsevier Ltd), 2010: 206-219.
2. Roos KL, Tunkel AR, Scheld WM. Acute bacterial meningitis. In: Scheld WM, Whitley RJ, Marra CM (eds). Infections of the Central Nervous System, Third ed Philadelphia; Lippincott-Wil-
liams and Wilkins, 2004: 347- 422.
3. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010; 23: 467–492.
4. Tunkel AR, van de Beeks D, Scheld MW. Acute meningitis. In: Mandell GL, Bennett JE, Dolin R (eds). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Seventh
ed, Philadelphia; Churchill Livingstone Elsevier, 2010:1189-1229.
5. McIntyre PB, O’Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet 2012; 380(9854): 1703-1711.
6. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med 2010; 362: 146-154.
7. Irani DN, Griffin DE. Approach to the patient with infection of the central nervous system. In: Gorbach SL, Barlett JG, Blacklow NR (eds). Infectious Diseases. Third ed, Philadelphia: Lippin-
cott Williams and Wilkins, 2004:1259–1263.
8. Tülek N, Fışgın Taşdelen N. Akut bakteriyel menenjitler. In: Willke Topcu A, Söyletir G, Doğanay M. Enfeksiyon Hastalıkları ve Mikrobiyolojisi (yazarlar). 3. Baskı, İstanbul: Nobel Tıp Kita-
bevleri, 2008: 1390-1422.
9. Zunt JR. Iatrogenic infections of the central nervous system. In: Scheld WM, Whitley RJ, Marra CM, eds. Infections of the central nervous system. Third ed, Philadelphia: Lippincott-Williams
and Wilkins, 2004: 569- 581.
10. Sacar S, Turgut H, Toprak S, et al. A retrospective study of central nervous system shunt infections diagnosed in a university hospital during a 4-year period. BMC Infect Dis 2006; 6: 43- 47.
11. Tülek N, Fışgın Taşdelen N. Akut bakteriyel menenjitler. In: Willke Topcu A, Söyletir G, Doğanay M. Enfeksiyon Hastalıkları ve Mikrobiyolojisi (yazarlar). 4. Baskı, İstanbul: Nobel Tıp Kita-
bevleri, 2017: 1275-1303.
12. Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev 2007; 31(1): 89–96.
13. Ouli X, Pollard A, Mueller JE, Norheim G.Emergence of Serogroup X Meningococcal Disease in Africa: Need for a Vaccine. Vaccine 2013; 31(27): 2852-2861.
14. Jin Z, Romero-Steiner S, Carlone GM, Robbins JB, Schneerson R. Haemophilus influenzae Type a Infection and Its Prevention. Infect Immun 2007; 75(6): 2650-2654.
15. Korczak B, Frey J, Schrenzel J, et al. Use of diagnostic mikroarrays for determination of virulence gene patterns of Escherichia coli K1, a major cause of neonatal meningitis. J Clin Microbiol
2005; 43(3):1024–1031.
16. Brouwer MC, Heckenberg SG, de Gans J, et al. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. Neurology 2010; 75:1533-1539.
17. van de Beek D, Brouwer M, Hasbun R, et al. Community-acquired bacterial meningitis. Nat Rev Dis Primers 2016; 2:16074 doi: 10.1038/nrdp.2016.74.
18. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease
Study 2010. Lancet 2012; 380: 2095–2128.
19. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011; 364:2016-2025.
20. Tsai CJ, Griffin MR, Nuorti JP, Grijalva CG. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect
Dis 2008; 46:1664-1672.
21. Bijlsma MW, Brouwer MC, Kasanmoentalib ES, et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study. Lancet Infect Dis 2016;
16:339-347.
22. Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis 2014; 14:813-819.
23. Oordt-Speets AM, Bolijn R, van Hoorn RC, et al. Global etiology of bacterial meningitis: A systematic review and meta-analysis. PLoS One 2018; 13:e0198772.
24. Bijlsma MW, Bekker V, Brouwer MC, et al. Epidemiology of invasive meningococcal disease in the Netherlands, 1960-2012: an analysis of national surveillance data. Lancet Infect Dis 2014;
14:805-812.
25. Ouldali N, Levy C, Varon E, et al. Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey. Lancet Infect
Dis 2018; 18:983-991.
26. Erickson TA, Munoz FM, Troisi CL, et al. The Epidemiology of Meningitis in Infants under 90 Days of Age in a Large Pediatric Hospital. Microorganisms 2021; 4;9(3):526. doi: 0.3390/mic-
roorganisms9030526.
27. Vallejo JG, McNeil JC, Hultén KG, et al. Invasive Haemophilus influenzae Disease at Texas Children’s Hospital, 2011 to 2018. Pediatr Infect Dis J 2019; 38:900-905.
28. Ceyhan M, Yildirim I, Balmer P, et al. A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis [serial on the Internet] 2008 Jul [date cited]. Available
from http:// wwwnc.cdc.gov/eid/article/14/7/07-0938.htm
29. Erdem H, Kilic S, Coşkun O, et al. and Members of the Turkish Bacterial Meningitisin the Elderly Study Group. Community-acquired acute bacterial meningitis in the elderly in Turkey. Clin
Microbiol Infect 2010; 16: 1223–1229.
30. Trotter CL, Lingani C, Fernandez K, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data. Lancet Infect Dis 2017; 17:867-872.
31. Bozio CH, Abdul-Karim A, Abenyeri J, et al. Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction
of 13-valent pneumococcal conjugate vaccine. PLoS One 2018; 13:e0203205.
32. van Samkar A, Brouwer MC, Schultsz C, et al. Streptococcus suis Meningitis: A Systematic Review and Meta-analysis. PLoS Negl Trop Dis 2015; 9:e0004191.
33. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39(9):1267- 1284.
34. Yezli S. The threat of meningococcal disease during the Hajj and Umrah mass gatherings: A comprehensive review. Travel Med Infect Dis 2018; 24:51.
35. McGill F, Heyderman RS, Panagiotou S, et al. Acute bacterial meningitis in adults. Lancet 2016; 388:3036-3047.
36. Doran KS, Fulde M, Gratz N, et al. Host-pathogen interactions in bacterial meningitis. Acta Neuropathol 2016; 131:185-209.
37. Sellner J, Täuber MG, Leib SL. Pathogenesis and pathophysiology of bacterial CNS infections. Handb Clin Neurol 2010; 96:1-16.
38. Koedel U, Klein M, Pfister HW. New understandings on the pathophysiology of bacterial meningitis. Curr Opin Infect Dis 2010; 23(3): 217-223.
39. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 2006; 7(4):354-359.
40. Pachter JS, de Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 2003;62(6):593-604.
41. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nature Rev Immunol 2012; 12: 623-635.
42. Koedel U, Scheld WM, Pfister HW. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2002; 2(12):721- 736.
43. Barichello T, Generoso JS, Collodel A, Moreira AP, Almeida SM. Pathophysiology of acute meningitis caused by Streptococcus pneumoniae and adjunctive therapy approaches. Arq Neurop-
siquiatr 2012; 70(5):366-372.
44. Tunkel AR, Scheld WM. Pathogenesis and pathophysiology of bacterial meningitis. Clin Microbiol Rev 1993; 6(2):118- 136.
45. Stephens DS, Farley MM. Pathogenic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae. Rev Infect Dis 1991;13(1):22- 33.
46. Burnaugh AM, Frantz LJ, King SJ. Growth of Streptococcus pneumoniae on human glycoconjugates is dependent upon the sequential activity of bacterial exoglycosidases. J Bacteriol 2008;
190(1):221-230.
47. Bogaert D, de Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4: 144–154.
48. Kostyanev TS, Sechanova LP. Virulence factors and mechanisms of antibiotic resistance of haemophilus influenzae. Folia Med (Plovdiv) 2012; 54 1):19-23.
49. Meli DN, Christen S, Leib SL, Tauber MG. Current concepts in the pathogenesis of meningitis caused by Streptococcus pneumoniae. Curr Opin Infect Dis 2002; 15: 253–257.
50. Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev 2011; 24(3):557-591.
51. Kim KS. Investigating Bacterial Penetration of the Blood-Brain Barrier for the Pathogenesis, Prevention, and Therapy of Bacterial Meningitis. ACS Infect Dis 2020; 6:34-42.
51. Gloor SM, Watctel M, Bolliger MF, Ishihara H, Landmann R, Frei K. Molecular and cellular permeability control at the blood-brain barrier. Brain Res Brain Res Rev 2001; 36(2): 258-264.
52. Strazeille N, Ghersi-Egea JF. Choroid plexus in the central nervous system; biology and physiopathology. J Neuropathol Exp Neurol 2000; 59(7): 561-574.
53. Prasadarao NV. Identification of Escherichia coli outer membrane protein A receptor on human brain microvascular endothelial cells. Infect Immun 2002; 70(8): 4556- 4563.
54. Pron B, Taha MK, Rambaud C, et al. Interaction of Neisseria maningitidis with the components of the blood-brain barrier correlates with an increased expression of PilC. J Infect Dis 1997;
176(5): 1285-1292.
55. Moreillon P, Majcherczyk PA. Proinflammatory activity of cell-wall constituents from gram-positive bacteria. Scand J Infect Dis 2003; 35(9):632-641.
56. Barichello T, dos Santos I, Savi GD, et al. TNF-alpha, IL-1beta, IL-6, and cinc-1 levels in rat brain after meningitis induced by Streptococcus pneumoniae. J Neuroimmunol 2010; 15(1-2):42-45.
57. Østergaard C, Brandt C, Konradsen HB, Samuelsson S.Differences in survival, brain damage, and cerebrospinal fluid cytokine kinetics due to meningitis caused by 3 different Streptococcus
pneumoniae serotypes: evaluation in humans and in 2 experimental models. J Infect Dis 2004;190(7):1212-1220.
58. Li MO, Flavell RA. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity 2008; 28(4):468-476.
59. Tülek N, Uysal G, Özhan B, Güven MA. Akut bakteriyel ve viral menenjitte serum ve BOS IL- 10 düzeyleri. FLORA Derg 1999;4(3):181- 186.
60. Leppert DS, Leib L, Grygar C, Miller KM, Schaad UB, Hollander GA. Matrix metalloproteinase (MMP)-8 and MMP- 9 in cerebrospinal fluid during bacterial meningitis: association with
blood-brain barrier damage and neurological sequelae. Clin Infect Dis 2000; 31: 80–84.
61. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Histol Histopathol 2004; 19(2):535-
564.
62. Opitz B, Eitel J, Meixenberger K, Suttorp N. Role of Toll-like receptors, NOD-like receptors and RIG-I-like receptors in endothelial cells and systemic infections. Thromb Haemost 2009;
102(6):1103-1109.
63. Barichello T, Savi GD, Silva GZ, et al. Antibiotic therapy prevents, in part, the oxidative stress in the rat brain after meningitis induced by Streptococcus pneumoniae. Neurosci Lett 2010;
478(2):93-96.
64. Nau R, Brück W. Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci 2002; 25: 38-45.
65. van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849-1859.
66. Weisfelt M, van de Beek D, Spanjaard L, et al. Community-acquired bacterial meningitis in older people. J Am Geriatr Soc 2006; 54:1500-1507.
67. Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998;
129:862869.
68. Scarborough M, Thwaites GE. The diagnosis and management of acute bacterial meningitis in resource-poor settings. Lancet Neurol 2008;7(7):637-648.
69. Fitch MT, van de Beek D. Emergency diagnosis and treatment of adult meningitis Lancet Infect Dis 2007; 7: 191-200.
70. Thomas KE, Hasbun R, Jekel J, Quagliarello VJ. The diagnostic accuracy of Kernig’s sign, Brudzinski sign and nuccal rigidity in adults with suspected meningitis. Clin Infect Dis 2002;35: 46-52.
71. Brouwer MC, Thwaites GE, Tunkel AR, van de Beek D. Dilemmas in the diagnosis of acute community-acquired bacterial meningitis. Lancet 2012;380(9854):1684-1692.
72. Mylonakis E, Hohmann EL, Calderwood SB. Central nervous system infection with Listeria monocytogenes. 33 years’ experience at a general hospital and review of 776 episodes from the
literature. Medicine (Baltimore) 1998; 77:313-336.
73. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328:21-28.
74. Park N, Nigo M, Hasbun R. Comparison of Four International Guidelines on the Utility of Cranial Imaging Before Lumbar Puncture in Adults with Bacterial Meningitis. Clin Neuroradiol
2022; 32:857-862.
75. Hasbun R, Abrahams J, Jekel J, Quagliarello VJ. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med 2001; 345:1727-1733.
76. Salazar L, Hasbun R. Cranial Imaging Before Lumbar Puncture in Adults With Community-Acquired Meningitis: Clinical Utility and Adherence to the Infectious Diseases Society of
America Guidelines. Clin Infect Dis 2017; 64:1657-1662.
77. Chaudhuri A, Martinez-Martin P, Kennedy PG, et al. EFNS Task Force EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on
acute bacterial meningitis in older children and adults. Eur J Neurol 2008;15(7):649-659.
78. Proulx N, Fréchette D, Toye B, Chan J, Kravcik S.Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM 2005; 98(4):291-298.
79. van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect 2016; 22 Suppl 3:37-62.
80. Wright BLC, Lai JTF, Sinclair AJ. Cerebrospinal fluid and lumbar puncture: a practical review. J Neurol 2012; 259:1530–1545.
81. Seehusen DA, Reeves MM, Demıtrı A, Fomin DA. Cerebrospinal fluid analysis. Am Fam Physician 2003; 68(6):1103-1108.
82. Mazor SS, McNulty JE, Roosevelt GE. Interpretation of traumatic lumbar punctures: Who can go home? Pediatrics 2003; 111(3): 525- 528.
83. Roos KL. Lumbar puncture. Semin Neurol 2003; 23(1): 105- 114.
84. Montes K, Jenkinson H, Habib OB, et al. Corrected white blood cell count, cell index, and validation of a clinical model for the diagnosis of health care-associated ventriculitis and meningitis
in adults with intracranial hemorrhage. Clin Neurol Neurosurg 2019; 178:36-41.
85. Hasbun R, Tunkel AR. Approach to the patient with central nervous system infection. In: Principles and Practice of Infectious Diseases, 9th ed, Bennett JE, Dolin R, Blaser MJ (Eds), Elsevier
Saunders, Philadelphia 2020. p.1176.
86. Greeenlee JE, Carroll KC. Cerebrospinal fluid in central nervous system infections. In Scheld WM, Whitley RJ, Marra CM (eds). Infections of The Central Nervous System. Third ed. Phila-
delphia: Lippincott Williams and Wilkins, 2004; 5-30.
87. Huy NT, Thao NT, Diep DT, et al. Cerebrospinal fluid lactate concentration to distinguish bacterial from aseptic meningitis: a systemic review and meta-analysis. Crit Care 2010; 14:R240.
88. Leib SL, Boscacci R, Gratzl O, Zimmerli W. Predictive value of cerebrospinal fluid (CSF) lactate level versus CSF/blood glucose ratio for the diagnosis of bacterial meningitis following neuro-
surgery. Clin Infect Dis 1999; 29 (1):69-74.
89. Cunha BA. Distinguishing bacterial from viral meningitis: the critical importance of the CSF lactic acid levels. Intensive Care Med. 2006; 32(8):1272- 1273.
90. Geiseler PJ, Nelson KE, Levin S, et al. Community-acquired purulent meningitis: a review of 1,316 cases during the antibiotic era, 1954-1976. Rev Infect Dis 1980; 2:725-745.
91. Kanegaye JT, Soliemanzadeh P, Bradley JS. Lumbar puncture in pediatric bacterial meningitis: defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic
pretreatment. Pediatrics 2001; 108:1169.
92. Nigrovic LE, Malley R, Macias CG, et al. American Academy of Pediatrics, Pediatric Emergency Medicine Collaborative Research Committee. Effect of antibiotic pretreatment on cerebrospi-
nal fluid profiles of children with bacterial meningitis. Pediatrics 2008;122(4):726-730.
93. Saha SK, Darmstadt GL, Yamanaka N, et al. Rapid diagnosis of pneumococcal meningitis: implications for treatment and measuring disease burden. Pediatr Infect Dis J 2005; 24:1093-1098.
94. Tzanakaki G, Tsopanomichalou M, Kesanopoulos K, et al. Simultaneous single-tube PCR assay for the detection of Neisseria meningitidis, Haemophilus influenzae type b and Streptococcus
pneumoniae. Clin Microbiol Infect 2005; 11:386-390.
95. Leber AL, Everhart K, Balada-Llasat JM, et al. Multicenter Evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for Detection of Bacteria, Viruses, and Yeast in Cerebrospinal Fluid
Specimens. J Clin Microbiol 2016; 54:2251-2261.
96. McGill F, Heyderman RS, Michael BD, et al. The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent
adults. J Infect 2016; 72:405-438.
97. González-Donapetry P, García-Rodríguez J, Cendejas-Bueno E. A case of a FilmArray® ME false negative in meningococcal meningitis. J Infect 2019; 79:277287.
98. Swartz MN. Bacterial meningitis–a view of the past 90 years. N Engl J Med 2004; 351:1826.
99. Oordt-Speets AM, Bolijn R, van Hoorn RC, et al. Global etiology of bacterial meningitis: A systematic review and meta-analysis. PLoS One 2018; 13:e0198772.
100. Proulx N, Fréchette D, Toye B, et al. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM 2005; 98:291-298.
101. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336:708-716.
102. Edberg M, Furebring M, Sjölin J, Enblad P. Neurointensive care of patients with severe community-acquired meningitis. Acta Anaesthesiol Scand. 2011; 55(6):732-739.
103. Goldwater WN.Sefotaksim and ceftriaxone cerebrospinal fluid levels during treatment of bacterial meningitis in children. Int J Antimicrob Agents 2005; 26: 408–411.
104. Meyer CN, Samuelsson IS, Galle M, Bangsborg JM. Adult bacterial meningitis: aetiology, penicillin susceptibility, risk factors, prognostic factors and guidelines for empirical antibiotic treat-
ment. Clin Microbiol Infect 2004; 10: 709–717.
105. Bartt R.Acute bacterial and viral meningitis. Continuum (Minneap Minn). 2012;18(6 Infectious Disease):1255-1270.
106. Gilbert DN, Moellering RC, Elipoulas GM, Chambers HF, Saag Ms. The Sanford Guide to Antimicrobial Therapy. 43rd. Ed. USA Antimicrobial Therapy Inc 2013.
107. Ricard JD, Wolff M, Lacherade JC, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective
multicenter observational study. Clin Infect Dis 2007; 44: 250-255.
108. Kanellakopoulou K, Pagoulatou A, Stroumpoulis K, et al. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. J Antimicrob
Chemother 2008; 61: 1328-1331.
109. Punar M, Eraksoy H, Cagatay AA, et al. Neisseria meningitidis with decreased susceptibility to penicillin in Istanbul, Turkey. Scand J Infect Dis 2002;34(1):11- 13.
110. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369: 2196- 2210.
111. Ziai WC, Lewin JJ 3rd. Improving the role of intraventricular antimicrobial agents in the management of meningitis. Curr Opin Neurol 2009; 22:277-282.
112. Lu CH, Huang CR, Chang WN, et al. Community-acquired bacterial meningitis in adults: the epidemiology, timing of appropriate antimicrobial therapy, and prognostic factors. Clin Neurol
Neurosurg 2002; 104:352-358.
113. Tice AD, Strait K, Ramey R, et al. Outpatient parenteral antimicrobial therapy for central nervous system infections. Clin Infect Dis 1999; 29: 1394-1399.
114. Lindvall P, Ahlm C, Ericsson M, et al. Reducing intracranial pressure may increase survival among patients with bacterial meningitis. Clin Infect Dis 2004; 38: 384-390.
115. Bhatt SM, Lauretano A, Cabellos C, et al. Progression of hearing loss in experimental pneumococcal meningitis: correlation with cerebrospinal fluid cytochemistry. J Infect Dis 1993; 167:675-
683.
116. Freyer D, Manz R, Ziegenhorn A, et al. Cerebral endothelial cells release TNF-alpha after stimulation with cell walls of Streptococcus pneumoniae and regulate inducible nitric oxide synthase
and ICAM-1 expression via autocrine loops. J Immunol 1999; 163:4308-4314.
117. Lutsar I, Friedland IR, Jafri HS, et al. Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. J Antimicrob Chemother 2003;
52:651-655.
118. Mai NT, Tuan TV, Wolbers M, et al. Immunological and biochemical correlates of adjunctive dexamethasone in Vietnamese adults with bacterial meningitis. Clin Infect Dis 2009; 49:1387-
1392.
119. van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol 2010; 9: 254–263.
120. Heckenberg SG, Brouwer MC, van der Ende A, van de Beek D. Adjunctive dexamethasone in adults with meningococcalmeningitis. Neurology 2012; 79: 1563–1690.
121. van de Beek D, de Gans J. Dexamethasone in adults with communityacquired bacterial meningitis. Drugs 2006; 66 (4): 415–427.
122. Buke AC, Cavusoglu C, Karasulu E, Karakartal G. Does dexamethasone affect ceftriaxone penetration into cerebrospinal fluid in adult bacterial meningitis. Int J Antimicrob Agents 2003; 21
(5): 452- 456.
123. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD004405. DOI:
10.1002/14651858. CD004405.pub4.
124. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2015; :CD004405.
125. Ziai WC, Lewin JJ. Improving the role of intraventricular antimicrobial agents in the management of meningitis. Curr Opin Neurol 2009; 22: 277-282.
126. Weisfelt M, van de Beek D, Spanjaard L, Reitsma JB, de Gans J. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol
2006;5: 123-129.
127. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011; 364:2016-2025.
ASEPTİK VE VİRAL MENENJİTLER
KAYNAKLAR
1. Parasuraman TV, Frenia K, Romero J. Enteroviral meningitis. Cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 2001; 19:3-12.
2. Connolly KJ, Hammer SM. The acute aseptic meningitis syndrome. Infect Dis Clin North Am 1990; 4:599-622.
3. Tunkel AR, Beek DV, Scheld WM. Acute meningitis. Mandell GL, Bennett JE, Dolin R, ed. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 7. ed. Philadelphia:
Elsevier Churchill Livingstone. 2010:1189-1229.
4. Moore M. Centers for Disease Control. Enteroviral disease in the United States, 1970-1979. J Infect Dis 1982; 146:103-108.
5. Wilfert CM, Lauer BA, Cohen M, et al. An epidemic of echovirus 18 meningitis. J Infect Dis 1975; 131:75-78.
6. Midgley CM, Watson JT, Nix WA, et al. Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation.
Lancet Respir Med 2015; 3:879-887.
7. Bijlsma MW, Brouwer MC, Kasanmoentalib ES, et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study. Lancet Infect Dis 2016;
16:339-347.
8. Aseptic meningitis in adults – UpToDate.
9. Kupila L, Vuorinen T, Vainionpää R, et al. Etiology of aseptic meningitis and encephalitis in an adult population. Neurology 2006; 66:75-80.
10. Viral meningitis in children: Epidemiology, pathogenesis, and etiology – UpToDate.
11. Shen L, Chen CY, Huang D, et al. Pathogenic Events in a Nonhuman Primate Model of Oral Poliovirus Infection Leading to Paralytic Poliomyelitis. J Virol 2017 Jun 26;91(14):e02310-16. doi:
10.1128/JVI.02310-16. Print 2017 Jul 15.
12. Rager-Zisman B, Allison AC. The role of antibody and host cells in the resistance of mice against infection by coxsackie B-3 virus. J Gen Virol 1973; 19:329-338.
13. Abe Y, Fujii K, Nagata N, et al. The toll-like receptor 3-mediated antiviral response is important for protection against poliovirus infection in poliovirus receptor transgenic mice. J Virol 2012;
86:185-194.
14. Ida-Hosonuma M, Iwasaki T, Yoshikawa T, et al. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol 2005; 79:4460-4469.
15. Richer MJ, Lavallée DJ, Shanina I, Horwitz MS. Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. PLoS One 2009; 4:e4127. doi:
10.1371/journal.pone.0004127. Epub 2009 Jan 5.
16. Mahon BP, Katrak K, Nomoto A, et al. Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection
in transgenic mice expressing the human poliovirus receptor. J Exp Med 1995; 181:1285-1292.
17. Rose NR, Wolfgram LJ, Herskowitz A, Beisel KW. Postinfectious autoimmunity: two distinct phases of coxsackievirus B3-induced myocarditis. Ann N Y Acad Sci 1986; 475:146-156.
18. Woodruff JF. Viral myocarditis. A review. Am J Pathol 1980; 101:425-484.
19. Enterovirus and parechovirus infections: Epidemiology and pathogenesis – UpToDate.
20. Murray KO, Nolan MS, Ronca SE, et al. The Neurocognitive and MRI Outcomes of West Nile Virus Infection: Preliminary Analysis Using an External Control Group. Front Neurol 2018; 9:111.
21. Jaijakul S, Salazar L, Wootton SH, et al. The clinical significance of neutrophilic pleocytosis in cerebrospinal fluid in patients with viral central nervous system infections. Int J Infect Dis 2017;
59:77-81.
22. Shrikanth V, Salazar L, Khoury N, et al. Hypoglycorrhachia in adults with community-acquired meningitis: etiologies and prognostic significance. Int J Infect Dis 2015; 39:39-43.
23. Hasbun R, Rosenthal N, Balada-Llasat JM, et al. Epidemiology of Meningitis and Encephalitis in the United States, 2011-2014. Clin Infect Dis 2017; 65:359-353.
24. Leber AL, Everhart K, Balada-Llasat JM, et al. Multicenter Evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for Detection of Bacteria, Viruses, and Yeast in Cerebrospinal Fluid
Specimens. J Clin Microbiol 2016; 54:2251-2261.
25. Vanichanan J, Salazar L, Wootton SH, et al. Use of Testing for West Nile Virus and Other Arboviruses. Emerg Infect Dis 2016; 22(9):1587-1593.
26. Abedi GR, Watson JT, Nix WA, et al. Enterovirus and Parechovirus Surveillance – United States, 2014-2016. MMWR Morb Mortal Wkly Rep 2018; 67:515518.
27. Sulaiman T, Salazar L, Hasbun R. Acute versus subacute community-acquired meningitis: Analysis of 611 patients. Medicine (Baltimore) 2017; 96:e7984.
28. Jaijakul S, Arias CA, Hossain M, et al. Toscana meningoencephalitis: a comparison to other viral central nervous system infections. J Clin Virol 2012; 55:204-208.
29. Zakhour R, Aguilera E, Hasbun R, Wootton SH. Risk Classification for Enteroviral Infection in Children With Meningitis and Negative Gram Stain. Pediatr Emerg Care 2018; 34:791-796.
30. Levorson RE, Jantausch BA. Human parechoviruses. Pediatr Infect Dis J 2009; 28:831-832.
31. Calvert J, Chieochansin T, Benschop KS, et al. Recombination dynamics of human parechoviruses: investigation of type-specific differences in frequency and epidemiological correlates. J Gen
Virol 2010; 91:1229-1238.
32. Centers for Disease Control and Prevention (CDC). Nonpolio enterovirus and human parechovirus surveillance — United States, 2006-2008. MMWR Morb Mortal Wkly Rep 2010; 59:1577-
1580.
33. Boivin G, Abed Y, Boucher FD. Human parechovirus 3 and neonatal infections. Emerg Infect Dis 2005; 11:103-105.
34. Pham NT, Trinh QD, Khamrin P, et al. Diversity of human parechoviruses isolated from stool samples collected from Thai children with acute gastroenteritis. J Clin Microbiol 2010; 48:115-
119.
35. Harvala H, Robertson I, Chieochansin T, et al. Specific association of human parechovirus type 3 with sepsis and fever in young infants, as identified by direct typing of cerebrospinal fluid
samples. J Infect Dis 2009; 199:1753-1760.
36. Piñeiro L, Vicente D, Montes M, et al. Human parechoviruses in infants with systemic infection. J Med Virol 2010; 82:1790-1796.
37. McGill F, Griffiths MJ, Bonnett LJ, et al. Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study. Lancet Infect Dis 2018;
18:992-1003.
38. Shukla B, Aguilera EA, Salazar L, et al. Aseptic meningitis in adults and children: Diagnostic and management challenges. J Clin Virol 2017; 94:110-114.
39. Jakobsen A, Skov MT, Larsen L, et al. Herpes Simplex Virus 2 Meningitis in Adults: A Prospective, Nationwide, Population-Based Cohort Study. Clin Infect Dis 2022; 75:753-760.
40. Noska A, Kyrillos R, Hansen G, et al. The role of antiviral therapy in immunocompromised patients with herpes simplex virus meningitis. Clin Infect Dis 2015; 60:237-242.
41. Kaewpoowat Q, Salazar L, Aguilera E, et al. Herpes simplex and varicella zoster CNS infections: clinical presentations, treatments and outcomes. Infection 2016; 44:337-345.
42. Hasbun R. Acute Aseptic Meningitis Syndrome. In: Meningitis and Encephalitis: Management and Prevention Challenges, Hasbun R (Ed), Springer, 2018. p.43.
43. Fevola C, Kuivanen S, Smura T, et al. Seroprevalence of lymphocytic choriomeningitis virus and Ljungan virus in Finnish patients with suspected neurological infections. J Med Virol 2018;
90:429-435.
44. Talley P, Holzbauer S, Smith K, Pomputius W. Notes from the Field: Lymphocytic Choriomeningitis Virus Meningoencephalitis from a Household Rodent Infestation – Minnesota, 2015.
MMWR Morb Mortal Wkly Rep 2016; 65:248-249.
45. Ratzan KR. Viral meningitis. Med Clin North Am 1985; 69:399-413.
46. Bihan K, Weiss N, Théophile H, et al. Drug-induced aseptic meningitis: 329 cases from the French pharmacovigilance database analysis. Br J Clin Pharmacol 2019; 85:2540-2546